An observational study in Bypass Complication, Cardioplegia Solution Adverse Reaction and Endothelial Degeneration, sponsored by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Aortic Valve Stenosis with a site in Turkey — 9 open to participants now, 9 under way, 2 of them phase 3. Aortic Valve Stenosis · Turkey.
Among the 14 studies in Aortic Valve Stenosis with a site in Turkey, this one is one of 4 that started in 2022, is one of 6 observational ones, and was the 2nd registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →9 of the 14 studies in Aortic Valve Stenosis with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18+
Ankara Bilkent Sehir Hastanesi · Sites in Turkey
Ages 65+
Novartis Pharmaceuticals · Sites in Turkey, United States, Austria and 8 more countries
Ages 2–11
Medipol University · Sites in Turkey
Ages 18–85
Novartis Pharmaceuticals · Sites in Turkey, United States, Argentina and 20 more countries
Ages 6–11
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2022.
This study's enrollment of 74 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 60 across the 8 interventional studies, 87 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital is the lead sponsor of 5 studies on the registry; none are open to participants now.
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07794436Istanbul University - CerrahpasaAssociation Between Changes in Aortic Valve Area and Pulmonary Congestion After Transcatheter Aortic Valve Implantation | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Aortic Valve Stenosis with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Investigating the myocardial effects of cold blood cardioplegia and del nido cardioplegia solution, which are routinely used in clinical practice, will contribute to the studies in the literature on the safety and efficacy of these two methods.
For this purpose, patients with coronary artery disease that going to be Coronary Artery Bypass Graft (CABG) surgery will be classified within the scope of the SYNTAX score, the level of exposure to cardioplegia change in proportion to their score will be examined. Also, left ventricular muscle mass will be calculated in patients who will undergo Aortic Valve replacement (AVR) due to Aortic Stenosis, and myocardial protection level proportional to muscle mass will be examined, and cardioplegia efficiency will be compared.
Endocan, E-Selectin, TNF(Tumor Necrosis Factor)-alpha, Total Oxidant and Antioxidant status will be studied on sequential blood samples taken from patients who will undergo Elective Coronary Artery Bypass Grafting operation and aortic valve replacement, via retrograde cardioplegia cannula before induction, at the beginning of cardiopulmonary bypass and after removing the cross-clamp. With routinely used parameters like hemogram, lactate, liver and kidney function tests morbidity-mortality rates for specific cardioplegia technique will be compared
Patients diagnosed with coronary artery disease and aortic valve stenosis irrespectively
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects undergo Elective Coronary Artery Bypass Grafting with the use of cold blood cardioplegia solution for myocardial protection
Diagnostic Test: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Subjects undergo Elective Coronary Artery Bypass Grafting with the use of Del Nido cardioplegia solution as myocardial protection
Diagnostic Test: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Subjects undergo Aortic Valve Replacement with the use of cold blood cardioplegia solution as myocardial protection
Diagnostic Test: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Subjects undergo Aortic Valve Replacement with the use of Del Nido cardioplegia solution as myocardial protection
Diagnostic Test: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
Del Nido has beneficial effect for Endothelial function
Two groups with the protection of Del Nido cardioplegia solution, might have lesser Adverse outcomes from cardiopulmonary bypass and cross-clamping irrespectively, with measurements of BLOOD ENDOCAN (ng/ml) and E-SELECTIN LEVELS measured from venous blood specimens. Endocan and E-selectin levels to be measured by ELISA (ng/ml), expected to be much higher in the blood cardioplegia group because of the protective affect of Del nido cardioplegia. The venous blood specimens are going to be collected on different operation phases; after cannulation just before the beginning of cardiopulmonary bypass, after removing the cross-clamp before decannulation
Time frame: through study completion, an average of 1 year
Del Nido cardioplegia solution has lesser oxidative effect comparing to blood cardioplegia
Two groups with the protection of Del Nido cardioplegia solution, expected to be lesser oxidative affect with comparing of the TOTAL OXIDANT AND ANTIOXIDANT STATUS measured with specific assay kits from venous blood specimens First venous blood specimen will be taken from peripheral blood, 2nd and 3rd will be taken from coronary sinus blood through retrograde cardioplegia cannula; The venous blood specimens are going to be collected on different operation phases: 1st; after cannulation just before the beginning of cardiopulmonary bypass, 2nd; after removing the cross-clamp before decannulation
Time frame: through study completion, an average of 1 year
SYNTAX effect (SYNergy between PCI{Percutaneous Coronary Intervention} with TAXUS and Cardiac. Surgery)
The SYNTAX score has the potential to grade coronary anatomy and to guide patient selection toward the optimal revascularisation treatment to treat complex coronary artery disease (CAD). Subjects with Coronary Artery Disease might have proportional outcomes with SYNTAX score of individuals based upon parameters measured from venous blood specimens That means one wiht the higher SYNTAX score, expected to have higher difference in the blood cardioplegia group compared to Del Nido cardioplegia group because of the lesser protective affects to the myocardium. (ENDOCAN, E-SELECTIN, TOTAL OXIDANT AND ANTIOXIDANT STATUS measured by specific assay kits)
Time frame: through study completion, an average of 1 year
LVMI effect
In patients with severe symptomatic Aortic stenosis, concentric left ventricular(LV) geometry and severe LV hypertrophy by echocardiography have been associated with increased mortality after aortic valve replacement. So, demonstration of the relation of LV mass with myocardial protection levels might be important in the aortic stenosis patients for postoperative morbidity and mortality. Subjects with Aortic Valve Stenosis might have proportional outcomes with Left Ventricular Mass Index (LVMI) of individuals based upon parameters measured from venous blood specimens. (ENDOCAN, E-SELECTIN, TOTAL OXIDANT AND ANTIOXIDANT STATUS measured by specific assay kits)
Time frame: through study completion, an average of 1 year
Plan to share: Undecided
Ran from Oct 2022 to primary completion in Jul 2023, 9 months.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's 9 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital